Search

Your search keyword '"Hugo M van der Kuy"' showing total 2 results
Start Over Author "Hugo M van der Kuy" Publisher bmc
2 results on '"Hugo M van der Kuy"'

1. Evaluation of a group-based online informed consent conversation (eConsent) in participants from a low-risk vaccination clinical trial

Author

Ngoc H. Tan, Melvin Lafeber, Roos S. G. Sablerolles, Isabelle Veerman Roders, Anna van de Hoef, Karenin van Grafhorst, Leo G. Visser, Douwe F. Postma, Abraham Goorhuis, Wim J. R. Rietdijk, and P. Hugo M. van der Kuy

Subjects
Group, eConsent, Informed consent, Medicine (General), R5-920
Abstract

Abstract Background Electronic informed consent (eConsent) usage has expanded in recent years in Europe, especially during the pandemic. Slow recruitment rate and limitations in participant outreach are the challenges often faced in clinical research. Given the benefits of eConsent and group counselling reported in the literature, group eConsent was implemented in recruitment for the SWITCH-ON study. We aim to explore the experience of participants who attended group eConsent for the SWITCH-ON study and evaluate its potential for future use. Methods SWITCH-ON study aims to analyse the immunogenicity of a healthy population following bivalent COVID-19 booster vaccination. Four hundred thirty-four healthcare workers aged 18–65 were successfully recruited and sent a questionnaire about their experience with group eConsent. Out of 399 completed questionnaires (response rate 92%), 39 participants did not join group eConsent. The remaining 360 responses were included in the final analysis. Quantitative and qualitative data were reported using descriptive statistical analysis and thematic analysis respectively. Results Participants found that group eConsent was an efficient method that it allowed them to hear each other’s questions and concerns and created a sense of togetherness. However, limited privacy, barriers to asking questions in a group, and peer pressure can limit the use of group eConsent. One hundred sixty-five (46%) participants thought that group eConsent was suitable to recruit participants with diseases or conditions, while 87 (24%) reported limitations with this method. The remaining participants suggested that applicability of group eConsent depended on the diseases or conditions of the study population, and one-to-one conversation should always be available. Participants who had experienced both one-to-one and group eConsent shared different preferred consent formats for future studies. Conclusion Group eConsent was positively evaluated by the participants of a low-risk vaccination study. Participants advised using webinars to provide general information about the study, followed by an individual session for each participant, would retain the benefits of group eConsent and minimise the limitations it posed. This proposed setting addresses privacy questions and makes group eConsent easier to implement. Trial registration ClinicalTrials.gov NCT05471440 (registered on 22nd of July, 2022).

Published
2024
Full Text
View/download PDF

2. Control in the Hospital by Extensive Clinical rules for Unplanned hospitalizations in older Patients (CHECkUP); study design of a multicentre randomized study

Author

Aimée E. M. J. H. Linkens, Vanja Milosevic, Noémi van Nie, Anne Zwietering, Peter W. de Leeuw, Marjan van den Akker, Jos M. G. A. Schols, Silvia M. A. A. Evers, Carlota Mestres Gonzalvo, Bjorn Winkens, Bob P. A. van de Loo, Louis de Wolf, Lucretia Peeters, Monique de Ree, Bart Spaetgens, Kim P. G. M. Hurkens, Hugo M. van der Kuy, Pharmacy, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), Interne Geneeskunde, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: CAPHRI - R6 - Promoting Health & Personalised Care, Family Medicine, RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, RS: CAPHRI - R2 - Creating Value-Based Health Care, MUMC+: DA KFT Medische Staf (9), FHML Methodologie & Statistiek, MUMC+: MA Alg Interne Geneeskunde (9), and RS: Carim - B04 Clinical thrombosis and Haemostasis

Subjects
Geriatrics & Gerontology, IMPACT, Clinical decision support system, Study Protocol, ADMISSIONS, Older patients, Humans, Aged, RISK, Science & Technology, RC952-954.6, Multimorbidity, ADVERSE DRUG-REACTIONS, READMISSIONS, Hospitals, PREVALENCE, Hospitalization, Readmissions, Geriatrics, Quality of Life, Polypharmacy, Geriatrics and Gerontology, MEDICATION THERAPY MANAGEMENT, Life Sciences & Biomedicine, Gerontology, Medication optimisation, REVIEWS
Abstract

Background Due to ageing of the population the incidence of multimorbidity and polypharmacy is rising. Polypharmacy is a risk factor for medication-related (re)admission and therefore places a significant burden on the healthcare system. The reported incidence of medication-related (re)admissions varies widely due to the lack of a clear definition. Some medications are known to increase the risk for medication-related admission and are therefore published in the triggerlist of the Dutch guideline for Polypharmacy in older patients. Different interventions to support medication optimization have been studied to reduce medication-related (re)admissions. However, the optimal template of medication optimization is still unknown, which contributes to the large heterogeneity of their effect on hospital readmissions. Therefore, we implemented a clinical decision support system (CDSS) to optimize medication lists and investigate whether continuous use of a CDSS reduces the number of hospital readmissions in older patients, who previously have had an unplanned probably medication-related hospitalization. Methods The CHECkUP study is a multicentre randomized study in older (≥60 years) patients with an unplanned hospitalization, polypharmacy (≥5 medications) and using at least two medications from the triggerlist, from Zuyderland Medical Centre and Maastricht University Medical Centre+ in the Netherlands. Patients will be randomized. The intervention consists of continuous (weekly) use of a CDSS, which generates a Medication Optimization Profile, which will be sent to the patient’s general practitioner and pharmacist. The control group will receive standard care. The primary outcome is hospital readmission within 1 year after study inclusion. Secondary outcomes are one-year mortality, number of emergency department visits, nursing home admissions, time to hospital readmissions and we will evaluate the quality of life and socio-economic status. Discussion This study is expected to add evidence on the knowledge of medication optimization and whether use of a continuous CDSS ameliorates the risk of adverse outcomes in older patients, already at an increased risk of medication-related (re)admission. To our knowledge, this is the first large study, providing one-year follow-up data and reporting not only on quality of care indicators, but also on quality-of-life. Trial registration The trial was registered in the Netherlands Trial Register on October 14, 2018, identifier: NL7449 (NTR7691). https://www.trialregister.nl/trial/7449.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results